The Russian Ministry of Health has registered the drug "Elefusa" for the treatment of cancer

MOSCOW, October 6 - RIA Novosti. The Russian Ministry of Health has registered the drug "Elefusa" for the treatment of aggressive forms of breast and ovarian cancer, the press service of the pharmaceutical company Petrovax Pharm told RIA Novosti.

“The Russian Ministry of Health has registered the original drug Elefuza (INN: fusuloparib) for the treatment of advanced epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and metastatic HER2-negative breast cancer in patients with BRCA1/2 mutations. Registration of a selective PARP inhibitor allows us to expand the possibilities and availability of targeted therapy for these aggressive forms of cancer,” the statement says.

Head of the Oncology Department of the National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakova of the Ministry of Health of the Russian Federation Svetlana Khokhlova clarified that even after a successful first stage of treatment, about 70% of patients with ovarian cancer experience a relapse within three years, and with repeated courses of chemotherapy, approximately 80% of patients develop resistance to platinum drugs.

“Therefore, one of the key goals of treatment is to maximize the period without progression and maintain control of the disease. The emergence of another option in the class of PARP inhibitors expands the possibilities of maintenance therapy and gives doctors an additional tool for long-term control of the disease,” Khokhlova said, as quoted by the press service.